1. Introduction

Lentiviral vectors (LV) are efficient vehicles for gene transfer in mammalian cells due to their capacity to stably express a gene of interest in non-dividing and dividing cells. Their use has exponentially grown in the last years both in research and in gene therapy protocols, reaching 12% of the viral vector based clinical trials in 2011 [1]. This chapter reviews and discusses the state of the art on the production of HIV-1-based lentiviral vectors.

1.1. Lentiviruses

Lentiviruses are human and animal pathogens that are known to have long incubation periods and persistent infection. The time between the initial infection and the appearance of the first symptoms can reach several months or years [2]. Nowadays lentiviruses are classified as one of the seven genus of Retroviridae family. Lentivirus genus is composed by nine virus species that include primate and non-primate retroviruses (Figure 1) [3].

All Retroviruses share similarities in structure, genomic organization and replicative properties. Retroviruses are spherical viruses of around 80-120 nm in diameter [4] and are characterized by a genome comprising two positive-sense single stranded RNA. Also, they have a unique replicative strategy where the viral RNA is reverse transcribed into double stranded DNA that is integrated in the cellular genome [5]. Together with the RNA strands, the enzymes necessary for replication and the structural proteins form the nucleocapsid. The later is inside a proteic capsid that is surrounded by a double lipidic membrane [6]. Connecting the lipidic membrane and the capsid there are the matrix proteins. The lipidic membrane has its origin in the host cells and presents at surface the envelope viral glycoproteins (Env) (Figure 2).
Within the *Retroviridae* family, retroviruses can be classified as simple or complex. The complex retroviruses include the lentiviruses and spumaviruses presenting a more complex genome with additional regulation steps in their life cycle.

**Figure 1.** Lentiviruses taxonomy by the International Committee on Taxonomy of Viruses (ICTV).

**Figure 2.** Schematic representation of a retrovirus particle. Abbreviations: NC – nucleocapsid; MA – matrix; CA – capsid; SU – surface subunit of Env protein; TM – transmembrane subunit of Env protein; RT – reverse transcriptase; PR – protease; IN – integrase.
1.2. HIV-1 genome

HIV-1 genome has about 9-10 kb and is constituted by several non-coding sequences that control gene expression and protein synthesis, and genes that code for regulatory and accessory proteins in addition to the structural and enzymatic genes gag, pol and env, common to all retroviruses (Figure 3).

The gag gene codes for a polypeptide that is proteolytically cleaved by the viral protease (PR) originating three main structural proteins: matrix (MA), capsid (CA) and nucleocapsid (NC). The pro gene codes for a polypeptide that after cleavage by PR, during the virus maturation, originates PR, reverse transcriptase (RT) and integrase (IN). These enzymes play critical roles in the life cycle of retroviruses since their functions are the cleavage of viral polypeptides (also involved in virus maturation), the reverse transcription of viral RNA to double-stranded DNA (provirus) and the integration of the provirus into the cellular genome [7]. Finally the env gene encodes a polypeptide that is cleaved by cellular proteases in two proteins, the SU (surface) and TM (transmembrane) subunits. Together, these two proteins are the structural units of the Env protein that will interact with cellular receptors of the host cell allowing for virus entrance into the cell [10].

Flanking the retroviral provirus there are the 5’ and 3’ Long Terminal Repeats (LTRs) composed by the 3’ untranslated region (U3), repeat elements (R) and 5’ untranslated region (U5). The LTRs contain the enhancer/promoter sequence that allows for gene expression, the att repeats important for provirus integration and the polyadenylation signal (polyA).

The HIV-1 genome also has other six genes that code for two regulatory proteins (Tat and Rev), and four accessory proteins: Vif, Nef, Vpr, and Vpu. Tat protein interacts with cellular proteins and the mRNA TAR sequence acting by increasing the viral transcription hundreds of times. Rev interacts with Rev Responsive Element (RRE), a cis-acting sequence located in the middle of the env gene allowing the efficient nuclear export of unspliced or singly spliced messenger RNA. The functions of accessory proteins are related with pathogenesis of the virus and they are not crucial for the viral replication in-vitro.

The function of all HIV-1 proteins and their interactions with the host cells are not yet clearly understood but it is already reported that there are 2589 unique HIV-1–to–human protein interactions that are formed by 1448 human proteins [8,9].

Additionally to the coding sequences, the lentivirus genome also has several non-coding cis-acting sequences that play important roles in viral replication. The LTRs contains the Transactivator Response element (TAR) for the interactions of the complex formed by the Tat protein and transcriptional factors. After the 5’ LTR there are the primer binding site (PBS), where the reverse transcription starts, and the packaging signal (Ψ). Within the pol sequence there are also the central polypurine tract (cPPT) and the central termination sequence (CTS) contributing both for the efficient reverse transcription. Further there are the RRE in the middle of env gene and near the beginning of the 3’LTR the polypurine tract (PPT), a purine rich region where the synthesis of the plus strand DNA during the reverse transcription starts [10].
1.3. HIV-1 life cycle

The HIV-1 Life cycle starts when the Env glycoproteins GP120 located at surface of the viral envelope bind the CD4 cellular receptor and co-receptor CCR5, CSCR4 or both. This binding induces conformational changes of Env glycoproteins that allows for the fusion of the viral envelope with the cell membrane and the consequent entry of the viral core into the cell. Once inside the cell the capsid starts to disintegrate and the RT enzyme begins the reverse transcription where a double-stranded proviral DNA is synthesized using one of the positive single-strand viral RNA molecules as template. When reverse transcription is completed the double-strand DNA now called provirus forms a complex with viral proteins (RT, IN, NC, Vpr and MA) and cellular proteins termed pre-integration complex (PIC) that is imported to the cell nucleus by an ATP-dependent manner. It is this energy-dependent mechanism that allows the transduction of non-dividing cells by lentiviruses, unlike γ-retrovirus.

In the nucleus the linear provirus is integrated into the cellular genome by the integrase. Now all the requisites to produce new viruses are filled and the proviral DNA is transcribed into mRNA by the cellular RNA polymerase II. Still inside the nucleus some transcripts suffer a splicing event. The mRNA transcripts are exported from the nucleus to cytoplasm to be transcribed and to start to form the viral particles; two full-length RNA transcripts will be packaged in the viral particles.

The assembly of the viral proteins and the viral RNA occurs near the cellular membrane, in specific regions called lipid-rafts that are rich in cholesterol and sphingolipids. The immature viral particles are released from cells by budding. After leaving the cells, the viral protease cleaves the Gag and Pol proteins precursors to finally generate a mature infectious virion (reviewed by [5,10]).

2. Lentiviral vector development

The development of lentiviral vectors (LVs) started in 1989 when an HIV-1 provirus with *achloramphenicol acetyltransferase* (*cat*) reporter gene in place of the non-essential *nef* gene was constructed. The transfection of Jurkat cells with this modified provirus plasmid produced infectious replicative competent viruses, very similar with wild-type HIV-1, that could be used
as a tool for study HIV infection [11]. Few months after, the same group presented the first replication-defective HIV-1 vector. In a trans-complementation assay for measuring the replicative potential of HIV-1 envelope glycoprotein mutants they used an identical HIV-1 provirus construction but with a deletion in the \textit{env} gene. The Env glycoproteins were supplied by an independent expression plasmid. The co-transfection of these two plasmids allowed for the production of replication-defective viruses [12]. These vectors were structural identical to the wild-type virus, but lacked in their genome the \textit{env} gene. They could only perform a single cycle of replication because their host cells, after infection, did not have the \textit{env} gene to produce infectious virus. Although the principal aim of these studies was not the creation of viral vectors, they were the basis of lentiviral vector development, suggesting that lentiviruses could be adapted as a tool for genetic material transfer and permanent modification of animal cells.

Other preliminary studies were being conducted and several important discoveries or innovations had also contributed for the development of LVs. The introduction of the resistance marker gene \textit{hypoxanthine–guanine phosphoribosyl-transferase} (\textit{gpt}) under the expression control of SV40 promoter in the place of \textit{env} gene deletion allowed the first quantification of infectious LVs produced [13]. Like it had been observed for other \(\gamma\)-retroviral vectors (\(\gamma\)-RVs) it was possible to produce infectious lentiviral particles with Env glycoproteins from other viruses (pseudotyping); for example the Moloney Murine Leukemia Virus amphotrophic envelope 4070A (A-MoMLV) [13], and Human T-cell Leukemia Virus Type I (HTLV-I) envelope [14] were successfully used suggesting that \textit{env} gene was not necessary for virion particle formation. The localization and sequence of packaging signal was identified as the main responsible for the packaging of viral RNA [15] suggesting that modified RNAs with \(\Psi\) could also be packaged into virions. The discovery of the great stability conferred to LV pseudotyped with Vesicular Stomatitis Virus-G protein protein (VSV-G) allowed to concentrate the LV up to \(10^9\) by ultracentrifugation or ultrafiltration without significant loss of infectivity [16,17]. It was shown that LVs can transduce efficiently non-dividing cells, their principal advantage over the oncoretroviral vectors [16,18,19].

All these steps showed the potential of using modified lentiviruses as vectors, stimulating the iterative studies and the evolution of LVs in the next years. Their further development was based in safety principles (most of them already used in the development of oncoretroviral vectors) such as the splitting of the genome into several independent expression cassettes: the packaging cassette with the structural and enzymatic elements, the transfer cassettes with the gene of interest and the envelope expression cassette. In addition, the elimination of non-essential viral elements and the homology reduction among the expression cassettes also contributed to avoid the possibility of recombination, vector mobilization and the generation of replicative competent lentiviral vectors (RCLVs).

\textbf{2.1. Four generations of packaging constructs}

Four generations of LVs are currently considered; these differ from each other in terms of the number of genetic constructs used to drive the expression of the viral components, the number of wild-type genes retained as well as the number and type of heterologous \textit{cis}-elements used to increase vector titers and promote vector safety.
The system of three expression cassettes developed in 1996 by Naldini et al. [16] is considered the first generation of LVs. In this system the packaging cassette has all structural proteins, with exception of Env glycoproteins, and all accessory and regulatory proteins. Later the 5’ LTR was substituted by a strong promoter (CMV or RSV) and the 3’ LTR by an SV40 or insulin poly(A) site to reduce the homology between the cassettes. To prevent the packaging of viral elements the Ψ and PBS were deleted. In the env expression cassette the gp120 from HIV-1 was replaced by other env genes as VSV-G or amphotrophic MLV envelope (Figure 4). Finally the transgene cassette was composed by the 5’ LTR, the ψ with a truncated gag gene, the RRE cis-acting region and the gene of interest under the control of a heterologous promoter (usually CMV) and the 3’LTR [16,20]. This system allowed in an easy way to achieve good titers but its level of safety was not very high. RCL could be generated just with three recombination events by homologous recombination between the viral sequences in all cassettes or endogenous retroviral sequences in cells. In order to improve the safety and decrease the cytotoxicity of LVs, the three plasmid system was maintained, but all accessory genes not required for viral replication in vitro (vif, vpr, vpu, and nef) [21] were removed without negative effects on vector yield or infectivity. And in this way the second generation of LVs was developed (Figure 4) [22–25]. In the second generation, if by chance some RCL was generated, it would be unlikely to be pathogenic [26]. However the number of homologous events to generate RCL was the same as in the previous generation.

Reducing the lentiviral sequences by eliminating the tat and place the rev in an independent plasmid was the further step that originated the third generation of LV [27]. The tar sequence was replaced by a strong heterologous promoter. Therefore Tat protein was no longer necessary to increase the transgene transcription and tat gene was eliminated. This contributed for the reduction of lentiviral elements in the constructs. Rev was placed in an independent non-overlapping plasmid increasing the safety since now four events of homologous recombination were required for RCL formation [27]. With these new features, the vectors of third generation (Figure 4) presented a higher level of biosafety and, as the titers did not decreased, their use was widespread. Today they are the most commonly used LVs.

Although the formation of RCL was improbable, homologous recombination between the constructs was still possible since RRE sequence and part of packaging sequence in gag gene was in both transfer and structural packaging constructs. To solve these problems other solutions were developed originating the fourth generation of LV. The first approach used consisted in the replacement of the RRE sequences by heterologous sequences with similar functions that do not need the Rev protein. Some of these sequences were the Mason-Pfizer monkey virus constitutive transport element (CTE), the posttranscriptional control element (PCE) of the spleen necrosis virus and the human nuclear protein Sam68 [28–31]. The heterologous sequences increased the stability of the transcripts allowing their nuclear export. However the titers have decreased.

In 2000 a different approach based on codon optimization was implemented in lentiviral vector design [33]. This approach consists in perform silent mutations, changing the codon that codes for a certain aminoacid for other that codes for the same aminoacid, in principle, with a higher intracellular availability [32]. Applying this to the packaging and transfer con-
structs the homology between them was eliminated. These changes also allowed an independent expression of Rev since the sequences with suboptimal codon usage in HIV-1 genome, that conferred RNA instability and consequently lower expression, disappeared [32]. In the fourth generation (Figure 4) the homology between constructs were severely reduced but the titers had also been affected comparing with systems with the Rev/RRE [32]. Also, with the independence of Rev/RRE system, the level of biosafety decreased since the number of homologous recombination events for RCL formation was again three. Maybe due to these drawbacks the fourth generation has not been extensively used. However the codon optimization technology had been used to decrease the homology between sequences, improve the expression of viral components and viral titers [33].

Regarding the biosafety concerns about RNA mobilization and the possibility of generating RCLs, other improvements in packaging constructs were used and tested in transient LVs productions. These improvements relied on the concept of split-genome used for retroviral and lentiviral vector development but this time applied to the packaging construct. The gag-pol sequences were divided by two or three independent expression cassettes, disarming the functional gag-pol structure that is essential for vector mobilization [34]. In these systems additional recombination events between the several expression cassettes are necessary to generate RCLs which seems to contribute to a significant decrease of recombinant vectors formation with a functional gag-pol structure [35,36]. Although this increased LV safety the transduction efficiency and the LV production are challenged by the higher number of plasmids required [37].

![Figure 4](http://dx.doi.org/10.5772/52534)

2.2. Transfer vector

The transfer vector is the expression cassette of the transgene that will be packaged into the viral vector and integrated in the cellular genome of the target cells. Besides the gene of interest and the commonly heterologous promoter for transgene expression, the transfer expression cassette must have: the sequences responsible for the expression of the full-length transcript and its packaging into the newly formed virions in the producer cells; the sequences that will interact with viral and cellular proteins to allow an efficient reverse transcription, transport into the cellular nucleus and proviral integration into target cells genome. Despite the simple design and the lack of sequences that code for viral proteins, the transfer vector also evolved over the time. This evolution was primarily focused on safety by reducing and replacing the viral sequences by heterologous elements and in optimizing both safety and efficiency by the addition of several *cis*-acting elements to the transfer cassette [10].

The transfer vectors usually used in the first and second generation of packaging constructs LVs were composed by the 5’ LTR which include the TAR sequence, the PBS, the SD, the Ψ, the 5’ part of *gag* gene, the RRE sequence, the SA, an heterologous promoter followed by the gene of interest, the PPT and polyA within the 3’ LTR. The first hundreds of base pairs of *gag* are included after the packaging signal to increase the packaging efficiency (Figure 5). To avoid *gag* translation the initiation codon is usually mutated or cloned out of frame [16,20]. However, like it was previously found for γ-RVs, this transfer vector design with both wild-type LTRs can lead to integration genotoxicity and facilitates the mobilization of the transgene in the case of posterior infection of transduced cells [38]. To overcome these biosafety problems the LTRs of the transfer vector suffered additional changes. One of the first modifications was the replacement of the enhancer/promoter and Tar sequence of the 5’ LTR by a strong heterologous promoter allowing the transcription of the full-length viral RNA in a Tat-independent manner [25]. In addition the wild-type enhancer/promoter sequences in the U3 region of the 3´LTR were deleted originating the self-inactivating (SIN) LVs [27,39,40], as it had already been done for γ-RVs [41].

The SIN design (Figure 5) generates in the target cells a proviral vector without enhancer/promoter sequences in both LTRs. In producer cells the packaged RNA transcript does have the heterologous promoter in the 5’ end. Afterwards, in the target cells, during the reverse transcription, the U3 region of 3´LTR is copied and transferred to the 5’LTR. This transcriptional inactivation offered by the SIN design presents several safety advantages: prevents the formation of potentially packageable viral transcripts from the 5´LTR and consequently prevents vector mobilization by prior infection with a replicative retrovirus [39,42]; reduces the risk of insertional mutagenesis induced by the transcriptional interference of the LTRs in the neighboring sequences that can lead to the activation or up-regulation of oncogenes [43]; and lowers the risk of RCL formation by the reduction of the sequences with homology with wild-type virus.

The adoption of SIN design did not affected LV production as it happened with γ-RVs [27,39,40,44]. However both LVs and γ-RVs displayed high frequencies of read-through of the 3´ polyadenylation signal which can lead to the transcription of cellular sequences as oncogenes. This inefficient termination of transcription could suggest that some of the enhanc-
er/promoter sequences deleted can have a role in an efficient transcription termination [45]. In this context several improvements were done by the addition of heterologous elements to increase safety, expression and efficacy of LVs: heterologous polyadenylation signals in the 3’LTR could increase the efficiency of LVs and are particularly beneficial in the case of SIN LVs avoiding the read-through of cellular genes [40,46]; the chromatin insulators as the chicken hypersensitive site 4 (cHS4) sequence core from the β-globin locus control region (LCR) can reduce the interference from the neighboring regions in the vector and transgene expression [48]. Also these can improve the LV safety avoiding the full-length vector transcription or reducing long-distance effects of the integrated transgene promoter on neighboring cellular genes in the target cells. Additionally to the increased safety, insulators can help to maintain the gene expression over time preventing transcriptional silencing events in both producer and target cells [47–49]; incorporation of certain post-transcriptional regulatory elements (PRE) like the woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) near the 3’ untranslated region can also decrease the read-through in SIN vectors increasing the transgene expression and viral titers, [50–53]. The firsts WPRE sequences used contained part of a sequence that codes for a protein (WHV X) that has been reported a few times as related with carcinoma formation, posing safety concerns. However a further improved WPRE was created without this potential harmful sequence [54]; The cPPT sequence contributes for efficient reverse transcription and the proviral nuclear import processes. Although this non-essential sequence was not used in the firsts transfer vectors, its re-insertion increased the gene transfer efficiency [55–57].

Figure 5. Schematic representation of a non-SIN transfer vector (A) and a SIN transfer vector (B).

3. Pseudotyping

LVs, as other retroviral vectors, can incorporate in their viral particles Env glycoproteins from other enveloped viruses, a feature denominated pseudotyping. This was firstly demonstrated for the HIV-1-based lentiviral vector using a Moloney Murine Leukemia Virus amphotropic envelope 4070A (A-MoMLV) [13] and an Human T-cell Leukemia Virus Type I (HTLV-I) envelope [14].
In general the pseudotyped LVs have the tropism of the virus where glycoproteins are derived from, but there are some exceptions such as the glycoprotein of the Mokola virus, where the pseudotyped vectors did not present the specific neurotropism of the parental virus [58]. This ability of LVs to be pseudotyped showed to be advantageous since several glycoproteins could be tested to improve the transduction of cells with different receptors. As an example, HIV-based LVs pseudotyped with glycoprotein derived from the Rabies virus PV strain exhibited a great efficiency and neuronal tropism among the tested envelopes [59].

In addition to the tropism of LVs, the Env glycoproteins also affect vector structure and stability, the interactions with the target cells and the LV behavior during the infection. One example is LVs pseudotyped with rabies virus glycoprotein which allow for the retrograde axonal transport and access to the nervous system after peripheral infection [60]. Another example is the stability conferred to LVs by the VSV-G glycoproteins. The VSV-G glycoproteins are one of the most used Env proteins due to their wide tropism, with high titers achieved, great stability and resistance conferred to the LVs that allows for their concentration by ultracentrifugation. In addition they resist to freeze-thaw cycles, an important factor for storage of the vectors [16,18,19,61]. Despite these positive characteristics, the VSV-G protein is toxic for producer cells if expressed constitutively [17] and is inactivated by human serum complement [62], although this inactivation can be minimized using VSV-G conjugated with poly(ethylene glycol) [63].

Up to the present, several glycoproteins were used to pseudotype LVs (Table 1) each one presenting specific advantages and disadvantages that also depend on the LV application. Although LVs pseudotyped with different Env glycoproteins present different tropisms, being some tropisms more selective than others, in general these are not specific for a particular cell type as happens with HIV-1 glycoproteins [80,81]. For instance, the Ebola Zaire (EboZ) glycoprotein seems to be superior to other glycoproteins in the transduction of apical airway epithelia [72]. However also has been shown to transduce liver, heart, and muscle tissues [82].

This lack of specificity is not ideal from a clinical point of view, especially for in vivo gene therapy applications since it can lead to the infection of cells that do not need to be transduced [83].

Several strategies have been used to increase the specificity of infection in order to retarget the LVs to a cell of interest. These strategies consisted in genetic engineering of virus envelopes by deletion of some domains or fusing molecule-ligands (growth factors, hormones, peptides or single-chain antibodies) in several locations of the viral glycoproteins. The purpose is to choose cellular receptors specifically expressed on the target cells that will interact with the chimeric glycoproteins, restricting this way the vector tropism. A successful example was the removal of the heparan sulfate binding domain from the Sindbis virus envelope protein which effectively restricted the tropism of pseudotyped LVs to dendritic cells. This genetic modified Env protein interacts solely with the C-type lectin-like receptor almost exclusively on primary dendritic cells unlike its natural counterpart [84].
### Table 1. Lentiviral Vectors pseudotyped with various heterologous viral glycoproteins. Adapted from [78,79].

<table>
<thead>
<tr>
<th>Species/Envelope</th>
<th>Vectors</th>
<th>Comments</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vesicular stomatitis virus (VSV-G)</td>
<td>HIV-1, HIV-2, FIV, EIAV, SIV, BIV, JDV, CAEV</td>
<td>Very wide tropism. Presents resistance to high-speed centrifugation.</td>
<td>[16][64][65][66][66][66][67][67 – 69]</td>
</tr>
<tr>
<td>Feline endogenous retrovirus (RD114)</td>
<td>HIV-1, SIV</td>
<td>More efficient and less toxic than VSV-G in cells of the hematopoietic system</td>
<td>[70][71]</td>
</tr>
<tr>
<td>Ebola</td>
<td>HIV-1</td>
<td>Efficiently transduces airway epithelium</td>
<td>[72]</td>
</tr>
<tr>
<td>Lymphocytic choriomeningitis virus (LCMV)</td>
<td>SIV, HIV-1, FIV</td>
<td>Low toxicity</td>
<td>[73]</td>
</tr>
<tr>
<td>Rabies</td>
<td>HIV-1</td>
<td>Rabies confers retrograde transport in neuronal axons</td>
<td>[24]</td>
</tr>
<tr>
<td>Mokola</td>
<td>EIAV</td>
<td>Mokola selectively transduces RPE upon subretinal injection</td>
<td>[24][74]</td>
</tr>
<tr>
<td>Ross River virus</td>
<td>HIV-1, FIV</td>
<td>Transduces hepatocytes, glia cells and neurons</td>
<td>[75][76]</td>
</tr>
<tr>
<td>Sindbis virus</td>
<td>HIV-1</td>
<td>pH-dependent endosomal entry. Useful for vector targeting</td>
<td>[77]</td>
</tr>
<tr>
<td>Influenza virus hemagglutinin</td>
<td>HIV-1</td>
<td>Transduces airway epithelium</td>
<td>[72]</td>
</tr>
<tr>
<td>Moloney murine leukemia virus 4070 envelope</td>
<td>HIV-1, SIV</td>
<td>Able to transduce most cells</td>
<td>[18][16]</td>
</tr>
</tbody>
</table>

The envelope proteins engineered by fusion of natural ligands were in general able to bind to target cells. However the fusion domain of Env resulted generally in low vector titers since the ligand inhibits the fusogenic properties of the Env protein that allows for viral entry [85]. This approach seems to be more challenging but there are already improvements. One example is the LV pseudotyped with a chimeric glycoprotein of Sindbis virus covalently linked with mouse/human chimerical CD20-specific antibody which resulted in specific and stable transduction of CD20+ human lymphoid B cells. In this case the membrane fusion is triggered by the glycoprotein, in a pH-dependent manner, and it happens inside endocytic vesicles formed after antibody binding [86].

Other glycoproteins and ligands are being tested and used as well as alternative strategies to improve infection specificity of LVs [87–91].
4. Lentiviral vector production

The continuous research in LV development in the last twenty years and the acquired knowledge from the previous development of γ-RVs allowed the production of LVs with a significant biosafety level. However, to apply LVs to clinical use, they need to be easily and inexpensively produced and purified at a large-scale since, high concentrations of lentiviral particles are usually needed for efficient gene transfer in primary cells and the treatment of a single patient may require several liters of viral supernatant [92,93].

For large-scale and clinical-grade LV productions, a stable LV producer cell line seems to be the best approach for increased safety and well-characterized production process. However, unlike γ-RVs, the development of LV packaging cell lines has been more challenging because of the cytotoxicity of some viral proteins like Tat, Nef, Vpr, Rev, and PR [94]. Also VSV-G envelope, the typically envelope of choice for LV production because of its wide tropism and stability conferred to viral particles, is toxic for the producer cells. The VSV-G envelope can however be replaced by other non-toxic envelopes as the feline endogenous virus RD114 or the amphotropic MLV 4070A Env glycoproteins [33,95] and thus among the cytotoxic lentiviral proteins just the protease is still necessary for lentiviral vector production with the current packaging systems [93].

HIV protease mediates its toxicity in vitro and in vivo by cleaving procaspase 8, originating the casp8p41 fragment. This fragment induces mitochondrial depolarization leading to mitochondrial release of cytochrome C, activation of the downstream caspases 9 and 3 and nuclear fragmentation [96–98]. This cytotoxicity has hampered the development of stable cell lines.

The most used cells for LV production are the human embryonic kidney HEK-293 cell line and its genetic derivates the 293T (expressing the SV40 large-T antigen) and 293E (expressing the Epstein-Barr virus nuclear antigen-1, EBNA-1) cell lines. For clinical application human 293 and 293T cells have been the exclusive cell substrates [93]. Both cell lines can be used to produce LV in adherent systems and both can be easily adapted to serum-free suspension cultures. The 293T cells are most widely used because presents superior LV productivities compared with HEK-293 cells. However, the HEK-293 cell line may have an advantage in terms of safety as it lacks the SV40 large T antigen encoding gene (expressed in 293T cells) which is oncogenic [93,99,100]. In some research works other human or monkey derived cells have been used (other 293 derived clones, HeLa, HT1080, TE671, COS-1, COS-7, CV-1), although most of them showed lower LV titers [101]. However, COS-1 cells have shown to be capable of producing 3–4 times improved vector quality (expressed in infectious vector titer per ng of CA protein, p24), comparing with 293T cells, under serum-containing conditions [102].

4.1. Transient lentiviral vector production

Commonly LVs are produced by co-transfecting cells with the several expression cassettes harboring the transgene and the viral elements using chemical agents (e.g. calcium phos-
phate or polyethylenimine) and after 24 to 72 hours the LV are harvested [93]. This production system is fast and can be easily adapted to produce LVs with new genes of interest or with other Env glycoproteins. It is a simple process to apply at small scales commonly used in research, unlike the laborious development of a packaging cell line. However transient production is not the ideal choice for large and clinical LV productions since it is difficult to scale-up and requires large amounts of Good Manufacturing Practices (GMP) grade plasmid expressions cassettes turning the production more expensive [93,103]. In addition, transient LV production brings some biosafety problems like recombination between expression cassettes that could originate or facilitate the RCL formation. The recombination can occur in the mixture of transfection, inside the producer cells or during reverse transcription in the target cells since, generally after transfection cells have several copies of the plasmids which can contribute for the co-packaging of RNA transcripts [33,104]. Also batch to batch variability is common in transient productions since a population of transfected cells that expresses viral elements from episomal cassettes is generated. This can further complicate biosafety validation steps.

Nevertheless transient LV production is commonly used and recently it was shown that high titers of HIV-based LVs for clinical applications can be obtained by transient calcium phosphate transfection at large-scale under GMP conditions (Table 2) [99].

<table>
<thead>
<tr>
<th>Cell origin</th>
<th>Vector</th>
<th>Packaging generation</th>
<th>Envelope</th>
<th>Maximal titers (I.P./ml)</th>
<th>Observations</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>293 E</td>
<td>SIN HIV-1 based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>$1 \times 10^6$</td>
<td>PEI-mediated transfection</td>
<td>[107]</td>
</tr>
<tr>
<td>HEK293</td>
<td>HIV-1 based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>$1 \times 10^6$</td>
<td>PEI-mediated transfection</td>
<td>[101]</td>
</tr>
<tr>
<td>293T</td>
<td>HIV-1 based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>$2 \times 10^7$</td>
<td>Transfection with calcium phosphate</td>
<td>[99]</td>
</tr>
<tr>
<td>293T</td>
<td>HIV-1 based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>$1 \times 10^8$</td>
<td>Transfection by Flow Electroporation</td>
<td>[105]</td>
</tr>
</tbody>
</table>

Table 2. Transient LV productions. In this table they are presented several features of recent lentiviral productions in a transient manner.

There are several transfection agents that can be used to transfect mammalian cells as calcium phosphate, polyethylenimine (PEI) and cationic molecules (such as LipofectAMINE® and FuGENE®). For large scale only Ca-phosphate and PEI are used since the others are much more expensive. Both reagents are efficient but PEI is usually preferred since Ca-phosphate efficiency is highly sensitive to pH variations and can require serum or albumin to reduce Ca-phosphate cytotoxicity, unlike PEI [93]. However their use can raise some purity problems and can be cost-ineffective. Recently a method that does not use chemicals for transfection, flow electroporation, was used for transiently LV production at
large-scale [105]. The electroporation systems are normally used to transfect small volumes but flow electroporation addresses this limitation by continuously passing the desired volume of a cell and DNA suspension between two electrodes [106]. The procedure can be effectively scaled up for large bioprocessing avoiding additional costs and purification problems (Table 2) [105].

**4.2. Stable lentiviral vector production**

To overcome the biosafety problems in LV transient productions, inducible packaging cell lines have been developed (Table 3). The development of these systems is more time-consuming since after insertion of each expression cassette the population of stably transfected cells is usually screened for the best producer clone, like for γ-RVs, to maximize the LV production. However, these packaging cell lines are derived from one clone, therefore all the cells have the same growth and LV production behavior being the LV productions reproducible. This allows the generation of GMP cell banks, increasing safety conditions.

<table>
<thead>
<tr>
<th>Cell origin</th>
<th>Vector</th>
<th>Packaging generation</th>
<th>Envelope</th>
<th>Maximal titers (I.P./ml)</th>
<th>Observations</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>293T</td>
<td>HIV-1 based</td>
<td>2nd</td>
<td>VSV-G</td>
<td>1x10⁷</td>
<td>Tet-off</td>
<td>[108]</td>
</tr>
<tr>
<td>293T</td>
<td>HIV-1 based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>1.8x10⁶</td>
<td>Ecdysone inducible system. Codon-optimized gag-pol</td>
<td>[109]</td>
</tr>
<tr>
<td>293T</td>
<td>SIV-based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>1x10⁵</td>
<td>Ponasterone inducible system. Codon-optimized gag-pol</td>
<td>[110]</td>
</tr>
<tr>
<td>293T</td>
<td>HIV-1 based</td>
<td>2nd</td>
<td>VSV-G</td>
<td>3x10⁵</td>
<td>Tet-off. Codon-optimized gag-pol</td>
<td>[103]</td>
</tr>
<tr>
<td>293T</td>
<td>HIV-1 based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>3.4x10⁷</td>
<td>Tet-on</td>
<td>[111]</td>
</tr>
<tr>
<td>293T</td>
<td>EIAV based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>7.4x10⁵</td>
<td>Tet-on</td>
<td>[112]</td>
</tr>
<tr>
<td>293T</td>
<td>SIV-based</td>
<td>3rd</td>
<td>VSV-G</td>
<td>5x10⁷</td>
<td>Introduction of vector by concatemeric array transfection. Tet-off</td>
<td>[113]</td>
</tr>
<tr>
<td>293T</td>
<td>HIV-1 based</td>
<td>2nd</td>
<td>Ampho GaLV RDpro</td>
<td>1.2x10⁷ 1.6x10⁶ 8.5x10⁶</td>
<td>Continuous system. Codon-optimized gag-pol</td>
<td>[33]</td>
</tr>
</tbody>
</table>

Table 3. Lentiviral vector packaging cell lines. In this table they are presented several features of available packaging cell lines for LV production.
In conditional packaging cell lines the expression of cytotoxic proteins is under control of inducible promoters and the number of cells and growth conditions can be controlled, starting the LV production at a defined moment by adding an inductor or removing the suppressor from the culture medium. Originally the titers were low but further improvements in the expression cassettes design and optimization of the induction parameters led to similar levels of transient productions. However, such systems can only produce LV for a few days because of the activity of the cytotoxic viral proteins. In addition these packaging cells have often shown to be instable due to leaky expression of the cytotoxic viral elements that are under control of the inducible promoters and the need to add an inductor to the medium in some systems can add further difficulties to the purification process [93].

In 2003 Ikeda and co-workers have reported the development of a non-inducible packaging cell line that continuously produces LV for three months in culture (Table 3). However, significant titers could only be obtained after MLV-based vector transduction. This procedure raises serious problems from the biosafety point of view, since it increases the chances of RCL by homologous recombination, posing further concerns of co-packaging [37]. Nevertheless it was shown that it is possible to establish a cell line that can continuously produce LV although, until now no additional reports for this system appeared.

5. Lentiviral vector applications

Lentiviral vectors have emerged as powerful and versatile vectors for \textit{ex vivo} and \textit{in vivo} gene transfer into dividing and non-dividing cells. The particular characteristics of LVs allied to their marked development during the last years have triggered the attention of different fields, consequently a vast range of applications for these vectors, from fundamental biological research to human gene therapy have appeared. One of the applications of LVs is in genome-wide functional studies. The combination of synthetic siRNAs (small interfering RNA) or shRNAs (short hairpin RNAs) that can suppress the expression of genes of interest in mammalian cells [114], with engineered LVs allowed the formation of libraries like the Netherlands Cancer Institute (NKI) libraries, the RNAi consortium (TRC) libraries, the Hannon–Elledge libraries, and the System Biosciences (SystemBio) libraries for high-throughput loss-of-function screens in a wide range of mammalian cells [115]. For example, the TRC shRNA library has nearly 300,000 shRNAs targeting for 60,000 human and mouse genes [116]. The ability of LVs to achieve stable high-efficiency gene silencing in a wide variety of cells including primary cells, that are difficult to transduce, or non-dividing cells such as neurons thus greatly expanded the possibility of the RNAi screens [117].

Other application for LVs is in animal transgenesis. Genetic-modified animals can be created by infection of fertilized or unfertilized oocytes, single-cell embryos, early blastocysts, embryonic stem cells or by transduction of cells that are used as donors of nucleus for somatic cell nuclear transfer (SCNT) [10]. These animals (transgenic mice, rats, pigs, cows, chicken, monkeys) are used to understand gene function or biological processes, for validation of drug targets, for production of human therapeutic proteins and as preclinical models for human diseases [118].
Lentiviral vectors are being increasingly used for the cell genetic modification leading to cell-engineering applications. Stable gene transduction can be used for \textit{in vivo} imaging of vector infected cells. \textit{In vivo} imaging studies of cells, including stem cells, have become increasingly important to understand cell distribution, differentiation, migration, function, and transgene expression in animal models. As an example, LVs expressing the \textit{firefly} luciferase gene were used to monitor human embryonic stem cell (hESC) engraftment and proliferation in live mice after transplantation [119]. LVs can also be used to cellular reprogramming of somatic cells. More specifically, the promising induced pluripotent stem cells (iPS) can be generated from a somatic cell by transduction of four key transcription factors, Oct4, Sox2, Klf4, and c-Myc, using LVs[120,121]. iPS can be used to study stem cell biology, as a cellular platform for pharmacological and toxicological [122] and are considered a possible source of autologous stem cells for use in regenerative medicine. LVs also have been used in biotechnology to engineer cell lines for the production of proteins of interest [123].

The main goal of LV technology is their use in clinical gene therapy applications. Within this purpose considerable efforts have been made to increase the safety and efficacy of LVs. Proof-of-concept has been established in preclinical animal models since several research groups have reported that LVs could treat or cure a disease including \textit{β}-thalassaemia[124], sickle cell anemia [125], hemophilia B [126] and \textit{ζ}-chain-associated protein kinase of 70 kDa immunodeficiency [127]. Moreover, improvements in other genetic disorders like Parkinson’s disease [128], cystic fibrosis [129] and spinal muscular atrophy [130] have been reported.

LVs have more recently moved beyond the preclinical stage into the clinical arena. The first human clinical trial using LVs was initiated in 2003. In this, a VSV-G-pseudotyped HIV-based vector was engineered to conditionally express an antisense RNA against envelope glycoprotein in the presence of regulatory proteins provided by wild-type virus. Five subjects with chronic HIV infection received a single dose of gene-modified autologous CD4+ T cells which resulted in an increase of CD4+ T cells (in four out of the five subjects) and decrease in the viral load (in all five participants) after 1 year. Further studies over 2 years have not detected any adverse clinical events [131].

Since this first gene therapy clinical trial until June 2012, about 54 gene therapy clinical trials using LVs are ongoing or have been approved. Among them there are 12 trials for the treatment of HIV infection, 22 for the treatment of monogenic diseases (X linked cerebral adrenoleukodystrophy, Sickie cell anemia, Wiskott-Aldrich Syndrome, Metachromatic Leukodystrophy, X-Linked Chronic Granulomatous Disease, Inherited Skin Disease Netherton Syndrome, mucopolysaccharidosis type VII, \textit{β}-thalassemia, Fanconi Anemia Complementation Group A, X-Linked Severe Combined Deficiency, Adenosine Deaminase Deficient Severe Combined Immunodeficiency, Hemophilia A), 15 against various cancers, 2 for Parkinson’s disease, 3 for ocular diseases and 1 for patients with Stargardt Macular Degeneration [1].
6. Conclusions and outlook

The major concerns associated with the use of all retroviral vectors are the formation of replication competent retroviral vectors (RCR), the mutational integration of the provirus into the host cellular genome and mobilization of structural viral genes to target cells. In addition, the majority of developed LVs are HIV-derived raising further safety concerns since this is a well known human pathogen. Significant efforts have been made to develop LVs with improved biosafety and increased transduction efficiency. Some of those biosafety features include the splitting of viral elements by several expression cassettes, the use of self-inactivating vectors (SIN), decreasing to a minimum the number of viral elements and reducing homology between them.

Lentiviral vectors have already won its place as valuable and flexible tool for gene delivery, being used in several applications but further research is still ongoing towards the development of a lentiviral vector providing higher titers, higher robustness, lower toxicity and higher biosafety.

Lentiviral vector gene therapy is becoming a real alternative vector for therapy with dozens of clinical trials either been already performed or ongoing. These, together with the future incoming clinical trials, will enable to assess overall the pros and cons of the newcomer lentiviral vectors and will provide insights to further vector innovations that will be important to increase their productivity, quality and safety.

Acknowledgments

The authors acknowledge the financial support received from the Fundaçãopara a Ciência e a Tecnologia-Portugal (FCT) (PTDC/EBB-BIO/100491/2008 and PTDC/EBB-BIO/118621/2010). Hélio Antunes Tomás and Ana F. Rodrigues acknowledge FCT for their PhD grants (SFRH/BD/79022/2011 and SFRH/BD/48393/2008).

Author details

Hélio A. Tomás¹², Ana F. Rodrigues¹², Paula M. Alves¹² and Ana S. Coroadinha¹²

¹ Instituto de Tecnologia Química e Biológica, Universidade Nova de Lisboa, Oeiras, Portugal

² Instituto de Biologia Experimental Tecnológica, Oeiras, Portugal
References


a codon-optimized HIV-1 gag-pol gene. Journal of virology. 2000;74(10):4839–52. jvi.asm.org/content/74/10/4839.long (accessed 1 August 2012)


bloodjournal.hematologylibrary.org/content/96/10/3392.long (accessed 1 August 2012)


[81] Thaler S, Schnierle BS. A packaging cell line generating CD4-specific retroviral vectors for efficient gene transfer into primary human T-helper lymphocytes. Molecular


